How does VIP compare with PACAP, secretin, and other related peptides?

VIP sits inside the secretin/glucagon superfamily, and the honest short answer is that it is nearly interchangeable with PACAP at the VPAC receptors, clearly separate from PACAP at PAC1, and only distantly related in function to the metabolic members of the same molecular family. That closeness matters commercially as well as biologically, because the differences that decide which of these peptides became a marketed product are pharmacokinetic and hemodynamic rather than structural. Only one member of the group, secretin, holds an FDA approval, and it holds it as a diagnostic agent rather than a therapy.

What structural and evolutionary features place VIP, PACAP, and secretin in the same peptide superfamily?

The family resemblance is not a matter of overall similarity, since these peptides diverge widely across most of their length. It concentrates in two places: the first few residues that switch the receptor on, and the amphipathic helix that holds the peptide in place while that switch is thrown. Conservation of that arrangement across fish, amphibians, and invertebrate chordates indicates the core signaling job predates the split of the modern family.

• N-terminal triplet: His-Ser-Asp or a close variant opens VIP, PACAP, secretin, glucagon, GLP-1, GIP.
• Two-domain binding: A disordered eight-residue activation segment precedes the amphipathic helix that docks the receptor's extracellular domain.
• C-terminal amidation: Most members are amidated, and removing the amide sharply cuts potency, so synthetic versions require it.
• Conservation depth: PACAP ranks among the most conserved vertebrate peptides, human and fish sequences nearly identical.

How do receptor binding profiles differ between VIP and PACAP across VPAC1, VPAC2, and PAC1?

The common assumption that VIP and PACAP are distinguishable by affinity holds at only one of their three receptors. At VPAC1 and VPAC2 they are effectively the same molecule from the receptor's point of view, which means any result obtained through VPAC signaling alone cannot be assigned to one peptide over the other. PAC1 is the entire functional separation, and it is where PACAP's neurotrophic, catecholamine-releasing, and migraine-triggering effects originate.

In what ways does secretin's biological role diverge from VIP despite their shared ancestry?

Shared ancestry has not produced shared work. Secretin operates as a classical circulating hormone with one narrow job, a chemical trigger in the gut lumen and a bicarbonate response from the pancreas and biliary tree, while VIP is stored in nerve terminals and acts locally on smooth muscle, epithelium, endothelium, and immune cells. That contrast between focus and breadth is what put secretin into routine clinical use and left VIP without an approved product.

• Release trigger: Secretin exits duodenal S cells when luminal pH falls below roughly 4.5.
• Delivery mode: VIP releases from nerve terminals and acts locally rather than circulating hormonally.
• Receptor reach: Secretin receptors sit mainly on pancreatic and bile duct cells, VPAC receptors near-ubiquitous.
• Clinical record: Secretin's late-1990s autism trials failed repeatedly under placebo control despite open-label enthusiasm.

Which members of the family share VIP's anti-inflammatory and immune-modulating activity?

Only one family member genuinely reproduces VIP's immune profile, and the reason is mechanical rather than coincidental: immune cells carry VPAC1 constitutively and VPAC2 on activation, and PACAP hits both with the same force VIP does. The documented effects run across endotoxemia, collagen-induced arthritis, experimental colitis, and experimental autoimmune encephalomyelitis, which is a substantial preclinical record with no approved drug behind it.

How do plasma half-life and enzymatic degradation compare across these peptides?

Short half-life is the one property every member of this superfamily shares, and it is a direct consequence of the N-terminus that makes them work. Beginning with His-Ser presents an ideal substrate to dipeptidyl peptidase IV, and because that same segment is required for receptor activation, evolution could not shield it without disabling the peptide. That constraint is why the commercially successful members of the wider family are engineered analogs rather than the native molecules.

Where do glucagon, GLP-1, GIP, and GHRH sit relative to VIP within the same superfamily?

One molecular chassis carries two functional branches. The neuropeptide branch handles vasculature, smooth muscle, exocrine tissue, nerves, and immune cells, while the metabolic branch governs glucose handling, appetite, intestinal growth, and pituitary growth hormone release. GHRH is the boundary case, close enough to VIP in structure that early work explored overlapping activity, though the GHRH receptor is selective in practice and the crossover carries no physiological weight.

What problems arise from receptor cross-reactivity when one family member is given exogenously?

There is no such thing as a clean systemic dose of native VIP or PACAP. VPAC1 and VPAC2 sit on vascular and airway smooth muscle alongside immune cells, epithelium, and islets, so whatever the intended target, arteriolar relaxation arrives with it at doses at or below those needed for the desired effect. The clearest picture of what unopposed receptor activation looks like comes from a natural experiment rather than a trial.

How have the clinical and research development paths of VIP, PACAP, and secretin diverged?

Eighty-seven years separate the discovery of secretin from the discovery of PACAP, and the development histories are just as far apart. Secretin ended up the only member in routine clinical use, and its advantage is instructive: a single, well-defined, easily measured action suits a diagnostic bolus, where a short half-life is an asset rather than an obstacle. PACAP took the most unexpected turn of the three, moving away from agonism entirely once human infusion studies showed what the peptide reliably provokes.

1. 1902, secretin: Identified as the substance that gave the concept of a hormone its name.
2. 1970, VIP: Isolated from porcine intestine on the strength of its vasodilator activity.
3. 1989, PACAP: Found through its ability to stimulate adenylate cyclase in pituitary cells.
4. VIP programs: Aviptadil, a synthetic VIP, has been given intravenously in respiratory failure trials and inhaled for pulmonary arterial hypertension and sarcoidosis, with a phentolamine combination marketed for erectile dysfunction in parts of Europe.
5. PACAP programs: Development pivoted from neuroprotective agonism to blockade, with anti-PACAP ligand antibodies performing better in clinical testing than PAC1 receptor blockade.
6. Current focus: Receptor-selective and protease-resistant analogs, local or inhaled delivery, and VPAC1-targeted radiolabeled tracers in prostate, breast, and lung tumors.